The current state of immunotherapy for gliomas: an eye toward the future

2019 ◽  
Vol 131 (3) ◽  
pp. 657-666 ◽  
Author(s):  
Peter E. Fecci ◽  
John H. Sampson
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Checkpoint Blockade ◽  
Oncolytic Viruses ◽  
Current State ◽  
Wide Range ◽  
The Future

The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.

scholarly journals PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors

2020 ◽  
Vol 80 (21) ◽  
pp. 4731-4740 ◽  
Author(s):  
Surya Murty ◽  
Louai Labanieh ◽  
Tara Murty ◽  
Gayatri Gowrishankar ◽  
Tom Haywood ◽  
...  
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Reporter Gene ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Reporter Gene Imaging

Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors

2018 ◽  
Vol 29 (10) ◽  
pp. 1083-1097 ◽  
Author(s):  
Michael A. Morgan ◽  
Axel Schambach
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor

scholarly journals Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

Cancer Cell ◽  
2019 ◽  
Vol 35 (2) ◽  
pp. 221-237.e8 ◽  
Author(s):  
Hongwei Du ◽  
Koichi Hirabayashi ◽  
Sarah Ahn ◽  
Nancy Porterfield Kren ◽  
Stephanie Ann Montgomery ◽  
...  
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor

Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors

2017 ◽  
Vol 390 ◽  
pp. 188-200 ◽  
Author(s):  
Shuanglin Han ◽  
Olivier Latchoumanin ◽  
Guang Wu ◽  
Gang Zhou ◽  
Lionel Hebbard ◽  
...  
Keyword(s):  
Clinical Trials ◽  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor

scholarly journals Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

2017 ◽  
Vol 25 (1) ◽  
pp. 259-273 ◽  
Author(s):  
Lynsey M. Whilding ◽  
Ana C. Parente-Pereira ◽  
Tomasz Zabinski ◽  
David M. Davies ◽  
Roseanna M.G. Petrovic ◽  
...  
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Integrin Expression ◽  
Engineered T Cells ◽  
Αvβ6 Integrin

scholarly journals IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors

2021 ◽  
Author(s):  
tian chi ◽  
yan zou
Keyword(s):  
T Cells ◽  
Cancer Cells ◽  
Solid Tumors ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Xenograft Model ◽  
Cytokine Signaling ◽  
General Strategy ◽  
Car T Cells ◽  
Car T

Chimeric antigen receptor (CAR) T cell therapy has been successful in treating hematological malignancy, but solid tumors remain refractory. Here, we demonstrated that knocking out transcription factor IKZF3 in HER2-specific CAR T cells targeting breast cancer cells did not affect proliferation or differentiation of the CAR T cells in the absence of tumors, but markedly enhanced killing of the cancer cells in vitro and in a xenograft model. Furthermore, IKZF3 KO had similar effects on the CD133-specific CAR T cells targeting glioblastoma cells. AlphaLISA and RNA-seq analyses indicate that IKZF3 KO increased the expression of genes involved in cytokine signaling, chemotaxis and cytotoxicity. Our results suggest a general strategy for enhancing CAR T efficacy on solid tumors.

scholarly journals Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2818
Author(s):  
Anna Pasetto
Keyword(s):  
T Cells ◽  
Solid Tumors ◽  
Clinical Application ◽  
Nobel Prize ◽  
Chimeric Antigen Receptor ◽  
Winning Strategy ◽  
Antigen Receptor ◽  
Check Point ◽  
Car T Cells ◽  
Car T

In the recent years, immunotherapy has achieved impressive results utilizing different approaches, from (chimeric antigen receptor) CAR-T cells directed against CD19 for the treatment of leukemia and lymphomas to the Nobel prize-winning strategy of check-point inhibition for the treatment of several solid tumors [...]

Sign in / Sign up

Export Citation Format

Share Document